Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 16/20 | 0.44 |
| ▸ | PI4KA | P42356 | 1/20 | 0.42 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.42 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.42 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | DHFR | P00374 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5391550 | 0.81 | CDK1 (0.47) | TLR7CDK1CCNB1CCNE1CDK2 | |
| SCHEMBL2201074 | 0.78 | TLR7 (0.57) | TLR7PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL3441104 | 0.76 | MEN1 (0.50) | TLR7DHFRADORA2AADORA2BADORA1 | |
| SCHEMBL2200949 | 0.72 | PDE8B (0.41) | TLR7PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL3441092 | 0.71 | TLR7 (0.43) | TLR7CDK1CCNB1CCNE1CDK2 | |
| SCHEMBL3441218 | 0.71 | HSP90AA1 (0.49) | TLR7ADORA2AADORA2BADORA1TLR8 | |
| SCHEMBL1847650 | 0.71 | HSP90AA1 (0.42) | CDK1CCNB1CCNE1CDK2DHFR | |
| SCHEMBL3441043 | 0.70 | HSP90AA1 (0.50) | TLR7ADORA2AADORA2BADORA1TLR8 | |
| SCHEMBL14224935 | 0.69 | ADORA2A (0.50) | TLR7PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL468531 | 0.68 | CYP2D6 (0.53) | TLR7DHFRTLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7238700-B2 | A2B adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| EP-1401837-B1 | PURINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS INC (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20040209899-A1 | A2B adenosine receptor antagonists | PALLE VENKATA (IN) | 2004-10-21 | — | — | US | disclosed |
| US-6770651-B2 | THERAPY FOR ASTHMA, DIARRHEA | PALLE VENKATA (US) | 2004-08-03 | — | — | US | disclosed |
| EP-1401837-A1 | PURINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20030064999-A1 | A2B adenosine receptor antagonists | PALLE VENKATA (US) | 2003-04-03 | — | — | US | disclosed |
| WO-2003006465-A1 | PARTIAL AND FULL AGONIST OF A ADENOSINE RECEPTORS | CV THERAPEUTICS, INC. (US) | 2003-01-23 | — | — | WO | disclosed |
| WO-2003002566-A1 | PURINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064999-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | TLR7 1635/4885PI4KA 1911/4885PI4K2B 980/4885 |
| US-20040209899-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | TLR7 854/4885PI4KA 1633/4885PI4K2B 771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.